Sarpac - Project
Project
The SARPAC trial is a randomized, multi-centre, interventional, open-label, study with the aim to investigate the efficacy of sagramostim (Leukine®, Partner Therapeutics) in severe COVID-19 patients. Sagramostim is a Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and is known to be beneficial in viral pneumonia, by stimulating the differentiation of innate immune cells in the lungs called alveolar macrophages. To test the efficacy, 80 patients (40 COVID-19 patients with acute respiratory failure and 40 controls) were been enrolled in the study.
https://vimeo.com/540581394/4bae83fbfd
Repurposing of existing drugs for the treatment of COVID-19
The SARPAC trial is a randomized, multi-centre, interventional, open-label, study that enrolled 80 patients (40 COVID-19 patients with acute respiratory failure and 40 controls) to investigate the efficacy of Sagramostim (Leukin®, Partner Therapeutics) in severe COVID-19 patients.
Sagramostim as a viable treatment option
Sagramostim is a Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and is known to be beneficial in viral pneumonia (influenza). The SARPAC study showed that severe COVID-19 patients benefit from GM-CSF treatment.